Antidiabetics Market Analysis

  • Report ID: 6405
  • Published Date: Sep 18, 2025
  • Report Format: PDF, PPT

Antidiabetics Market Segmentation:

 Product Segment Analysis

Insulin segment is predicted to capture antidiabetics market share of over 53.5% by 2035, owing to its effective results in diabetic care. Insulin is one of the most preferred therapies for diabetes control and offers effective results in type 1 patients.  According to the National Institute of Diabetes and Digestive and Kidney Diseases, type 1 diabetic patients are suggested to take insulin as their bodies do not make it.  The ways to take insulin are through insulin pens, insulin pumps, and syringes, automated insulin delivery system or artificial pancreas is also an option to take insulin for some patients.

Patient Population Segment Analysis

The geriatric segment in antidiabetics market is expected to hold a dominant revenue share through the forecasted period. Senior people are more prone to chronic disorders such as diabetes and often require antidiabetics such as insulin to control and maintain their glucose levels. Obesity, lack of proper diet, and a sedentary lifestyle are prevalent among the older population, which contributes to a high risk of diabetes leading to growing sales of antidiabetics. For instance, according to the Endocrine Society report, 33% of diabetic patients are aged 65 or older, and have a high risk of developing diabetes-related issues such as kidney failure, heart disorder, and hypoglycemia.

Our in-depth analysis of the antidiabetics market includes the following segments:

Product

  • Insulin
  • Rapid Acting
  • Long Acting
  • Premixed Insulin
  • Short Acting
  • Drug Class
  • Biguanides
  • GLP-Agonists
  • Thiazolidinediones
  • Sulphonylureas
  • SGLT-2
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • Meglitinides

Patient Population

  • Pediatric
  • Adults
  • Geriatric

Route of Administration

  • Oral
  • Infusion
  • Intravenous
  • Insulin Pumps
  • Insulin Pen/Syringes 

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of antidiabetics is evaluated at USD 103.27 billion.

The global antidiabetics market size exceeded USD 94.9 billion in 2025 and is set to expand at a CAGR of around 9.8%, surpassing USD 241.71 billion revenue by 2035.

North America’s antidiabetics market is anticipated to capture 42.5% share by 2035, driven by the presence of cutting-edge diabetic research and treatment organizations, favorable reimbursement policies, and production of novel antidiabetic drugs by key market players.

Key players in the market include Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., and Novartis AG.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos